NASDAQ
SBBP

Strongbridge Biopharma plc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

Strongbridge Biopharma plc Stock Price

Vitals

Today's Low:
$1.9500
Today's High:
$2.0600
Open Price:
$1.9600
52W Low:
$1.43
52W High:
$4.63
Prev. Close:
$1.9700
Volume:
684684

Company Statistics

Market Cap.:
$0.137 billion
Book Value:
0.881
Revenue TTM:
$0.026 billion
Operating Margin TTM:
-205.72%
Gross Profit TTM:
$0.000 billion
Gross Profit TTM:
$0.000 billion
Profit Margin:
-205.02%
Return on Assets TTM:
-28.42%
Return on Equity TTM:
-75.8%

Company Profile

Strongbridge Biopharma plc had its IPO on 2015-10-16 under the ticker symbol SBBP.

The company operates in the Healthcare sector and Biotechnology industry. Strongbridge Biopharma plc has a staff strength of 71 employees.

Stock update

Shares of Strongbridge Biopharma plc opened at $1.96 at the start of the last trading session i.e. 2021-10-05.

The stocks traded within a range of $1.95 - $2.06, and closed at $2.

This is a +1.52% increase from the previous day's closing price.

A total volume of 684,684 shares were traded at the close of the day’s session.

In the last one week, shares of Strongbridge Biopharma plc have increased by 0%.

Strongbridge Biopharma plc's Key Ratios

Strongbridge Biopharma plc has a market cap of $0.137 billion, indicating a price to book ratio of 2.872 and a price to sales ratio of 4.4398.

In the last 12-months Strongbridge Biopharma plc’s revenue was $0.026 billion with a gross profit of $0.000 billion and an EBITDA of $-0.075 billion. The EBITDA ratio measures Strongbridge Biopharma plc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Strongbridge Biopharma plc’s operating margin was -205.72% while its return on assets stood at -28.42% with a return of equity of -75.8%.

In Q2, Strongbridge Biopharma plc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 27.7%.

Strongbridge Biopharma plc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG
0

Its diluted EPS in the last 12-months stands at $-1.053 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Strongbridge Biopharma plc’s profitability.

Strongbridge Biopharma plc stock is trading at a EV to sales ratio of 3.3031 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 4.4398.

Strongbridge Biopharma plc stock pays annual dividends of $None per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$0.000 billion
Total Liabilities
$0.000 billion
Operating Cash Flow
$0.000 billion
Capital Expenditure
$0.000 billion
Dividend Payout Ratio
0%

Strongbridge Biopharma plc ended 1970 with $0.000 billion in total assets and $131.2 billion in total liabilities. Its intangible assets were valued at $0.000 billion while shareholder equity stood at $0.000 billion.

Strongbridge Biopharma plc ended 1970 with $0.000 billion in deferred long-term liabilities, $0.000 billion in other current liabilities, billion in common stock, $0.000 billion in retained earnings and $0.000 billion in goodwill. Its cash balance stood at $0.000 billion and cash and short-term investments were $0.000 billion. The company’s total short-term debt was $0.000 billion while long-term debt stood at $0.000 billion.

Strongbridge Biopharma plc’s total current assets stands at $0.000 billion while long-term investments were $0.000 billion and short-term investments were $0.000 million. Its net receivables were $0.000 billion compared to accounts payable of $0.000 billion and inventory worth $0.000 billion.

In 1970, Strongbridge Biopharma plc's operating cash flow was $0.000 billion while its capital expenditure stood at $0.000 billion.

Comparatively, Strongbridge Biopharma plc paid $0 billion in dividends in 1970.

Other key metrics

Current Trading Price
$2
52-Week High
$4.63
52-Week Low
$1.43
Analyst Target Price
$8.29

Strongbridge Biopharma plc stock is currently trading at $2 per share. It touched a 52-week high of $4.63 and a 52-week low of $4.63. Analysts tracking the stock have a 12-month average target price of $8.29.

Its 50-day moving average was $0 and 200-day moving average was $0 The short ratio stood at 1.86 indicating a short percent outstanding of 2%.

Around 1091% of the company’s stock are held by insiders while 6815.1% are held by institutions.

Frequently Asked Questions About Strongbridge Biopharma plc

The stock symbol (also called stock or share ticker) of Strongbridge Biopharma plc is SBBP

The IPO of Strongbridge Biopharma plc took place on 2015-10-16

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$178.75
0
0%
$54.99
0
0%

Most Active

Last Price
Chg
Chg%
$58.63
-1.03
-1.73%
$92.12
-4.67
-4.82%
$5.12
-0.61
-10.65%
Apple Inc (AAPL)
$145.03
-5.62
-3.73%
$0.06
0.01
+12.74%

Top Gainers

Last Price
Chg
Chg%
$73
42.7
+140.92%
Oi S.A (OIBR-C)
$0
0
+100%
$0.02
0.01
+100%
$0.25
0.1
+66.44%
$2.85
1.01
+54.86%

Top Losers

Last Price
Chg
Chg%
$5.36
-22.58
-80.82%
$0.02
-0.06
-78.67%
Air T, Inc (AIRTW)
$0.01
-0.03
-75%
$4.51
-5.17
-53.41%
$11.5
-12.2
-51.48%

About

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company’s commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency. Its clinical-stage product candidates are Recorlev, a cortisol synthesis inhibitor, which is in a Phase III clinical trial that is used for the treatment of endogenous Cushing’s syndrome; and Veldoreotide, a somatostatin analog that completed Phase II clinical trial for the treatment of acromegaly. The company was formerly known as Cortendo plc and changed its name to Strongbridge Biopharma plc in September 2015. Strongbridge Biopharma plc was founded in 1996 and is based in Trevose, Pennsylvania.

Address

900 Northbrook Drive, Trevose, PA, United States, 19053